Skip to main content

Advertisement

Log in

Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature

  • Nephrology – Case Report
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

A 61-year old African-American woman presented with abdominal pain, tender splenomegaly, anemia, and renal insufficiency. Bone marrow biopsy demonstrated systemic mastocytosis. She was treated with mediator-specific therapy and imatinib, but her renal and hepatic function deteriorated and she required maintenance hemodialysis. Renal biopsy demonstrated interstitial infiltration with mast cells and acute tubular necrosis. Acute kidney injury in the setting of systemic mastocytosis and imatinib therapy is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Akin C (2005) Clonality and molecular pathogenesis of mastocytosis. Acta Haematol 114:61–69

    Article  PubMed  CAS  Google Scholar 

  2. Valent P et al (2001) Mastocytosis (mast cell disease). In: Jaffe ES et al (eds) World Health Organization (WHO) classification of tumors, tumors of hematopoietic and lymphoid tissues. IARC Press, Lyon, pp 291–302

    Google Scholar 

  3. Akin C, Metcalfe DD (2004) Systemic mastocytosis. Ann Rev Med 55:419–432

    Article  PubMed  CAS  Google Scholar 

  4. Kluin-Nelemans HC, Jansen JH, Breukelman J, Wolthers BG, Kluin PM, Kroon JM, Willemze R (1992) Response to interferon alfa-2b in a patient with systemic mastocytosis. NEJM 326:619–623

    Article  PubMed  CAS  Google Scholar 

  5. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzyme site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99:1741–1744

    Article  PubMed  CAS  Google Scholar 

  6. Talaszka A, Boulanger E, Monies Le, de Sagazan H, Le Blan C (1992) Acute kidney failure revealing mastocytosis. Presse Med 21(19):908–909

    PubMed  CAS  Google Scholar 

  7. Ali R, Ozkalemkas F, Ozkan A, Ozcelik T, Ozkocaman V, Akdag I, Ozan U, Tunali A (2006) Tumor lysis syndrome with acute renal failure during imatinib therapy. Leukemia Res 31:573–574

    Article  Google Scholar 

  8. Pou M, Saval N, Vera M, Saurina A, Sole M, Cervantes F, Botey A (2003) Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leukemia Lymphoma 44:1239–1241

    Article  PubMed  CAS  Google Scholar 

  9. Foringer JR, Verani RR, Tjia VM, Kinkel KW, Samuels JA, Guntupalli JS (2005) Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 39(12):2136–2138

    Article  PubMed  Google Scholar 

  10. El-Sharkawy MS, Siddiqui N, Aleem A, Al Diab A (2007) Renal involvement in lymphoma: prevalence and various patterns of involvement on abdominal CT. Int Urol Nephrol J 39:929–933

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Dean A. Kujubu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moore, A.E., Johnston, W.H., Hever, A. et al. Systemic mastocytosis presenting with acute oliguric renal failure: report of a case and review of the literature. Int Urol Nephrol 44, 639–642 (2012). https://doi.org/10.1007/s11255-010-9878-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-010-9878-5

Keywords

Navigation